Latest Options News

Glennon Small Companies Limited reported a robust FY25 with a 232.75% jump in net profit and declared final dividends, while strategically resetting its preference shares amid evolving small-cap market dynamics.

Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.

Global X Management (AUS) Limited has announced updated estimated distribution amounts for three of its ETFs listed on the ASX AQUA Market for the period ending 31 August 2025, alongside key dates for investors to note.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Entertainment Rewards Ltd reported a 12.7% increase in operating revenue for FY2025, driven by growth in key segments, but posted a wider net loss of $9.7 million amid higher expenses and a major convertible loan amendment.

Pure Hydrogen Corporation has raised A$1 million through a share placement with attaching options, aiming to accelerate its clean energy projects across Australia and the US.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

Humm Group Limited has announced a fully franked ordinary dividend of AUD 0.0075 per share for the six months ending June 2025, alongside a Dividend Reinvestment Plan offering.

Aeris Resources Limited reported a robust financial turnaround for FY25, posting a $45.2 million profit and a 68% rise in adjusted EBITDA, underpinned by steady copper and gold production and strategic refinancing.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.

Kalina Power Limited reported a net loss of AUD 4.67 million for FY25 with no revenue generated, while pursuing strategic asset sales and capital raising amid going concern uncertainties.

Advanced Braking Technology Ltd (ASX, ABV) reported a robust 25% revenue increase and 36% net profit growth for FY25, driven by international expansion and pioneering product launches in mining safety technology.